Citius Pharmaceuticals Inc (CTXR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Citius Pharmaceuticals Inc (CTXR) has a cash flow conversion efficiency ratio of -0.019x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.30 Million) by net assets ($69.08 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CTXR days of operational coverage to measure how many days the company can operate on defensive assets alone.
Citius Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Citius Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Citius Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Citius Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Form Bio Co. Ltd.
KQ:377220
|
-0.070x |
|
Grainger PLC
LSE:GRI
|
0.028x |
|
Alton Sports Co.Ltd
KQ:123750
|
0.190x |
|
iRobot Corporation
NASDAQ:IRBT
|
1.770x |
|
Jocil Limited
NSE:JOCIL
|
-0.200x |
|
Nam Sung
KO:004270
|
-0.009x |
|
EXA E&C Inc
KQ:054940
|
0.179x |
|
Delorean Corporation Ltd
AU:DEL
|
-0.423x |
Annual Cash Flow Conversion Efficiency for Citius Pharmaceuticals Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Citius Pharmaceuticals Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see CTXR market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $77.53 Million | $-26.55 Million | -0.342x | +10.01% |
| 2024-09-30 | $74.10 Million | $-28.20 Million | -0.381x | -19.74% |
| 2023-09-30 | $91.43 Million | $-29.06 Million | -0.318x | -15.91% |
| 2022-09-30 | $103.43 Million | $-28.36 Million | -0.274x | -50.15% |
| 2021-09-30 | $132.78 Million | $-24.25 Million | -0.183x | +63.68% |
| 2020-09-30 | $33.67 Million | $-16.93 Million | -0.503x | +1.44% |
| 2019-09-30 | $24.38 Million | $-12.44 Million | -0.510x | -25.61% |
| 2018-09-30 | $27.87 Million | $-11.32 Million | -0.406x | -11.83% |
| 2017-09-30 | $21.95 Million | $-7.97 Million | -0.363x | -3.20% |
| 2016-09-30 | $16.77 Million | $-5.90 Million | -0.352x | -109.37% |
| 2015-09-30 | $-635.21K | $-2.39 Million | 3.755x | +295.18% |
| 2014-09-30 | $-741.93K | $-705.05K | 0.950x | +530.18% |
| 2013-09-30 | $93.27K | $-20.60K | -0.221x | -149.83% |
| 2012-09-30 | $-45.85K | $-20.32K | 0.443x | -49.14% |
| 2011-09-30 | $-23.84K | $-20.78K | 0.872x | -- |
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-… Read more